These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23180582)

  • 1. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence.
    Liu Y; Hawkins OE; Su Y; Vilgelm AE; Sobolik T; Thu YM; Kantrow S; Splittgerber RC; Short S; Amiri KI; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    EMBO Mol Med; 2013 Jan; 5(1):149-66. PubMed ID: 23180582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Senescence-associated secretory factors induced by cisplatin in melanoma cells promote non-senescent melanoma cell growth through activation of the ERK1/2-RSK1 pathway.
    Sun X; Shi B; Zheng H; Min L; Yang J; Li X; Liao X; Huang W; Zhang M; Xu S; Zhu Z; Cui H; Liu X
    Cell Death Dis; 2018 Feb; 9(3):260. PubMed ID: 29449532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
    Liu Y; Hawkins OE; Vilgelm AE; Pawlikowski JS; Ecsedy JA; Sosman JA; Kelley MC; Richmond A
    Clin Cancer Res; 2015 Dec; 21(23):5338-48. PubMed ID: 26152738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
    Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
    ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
    Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
    Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
    Huck JJ; Zhang M; McDonald A; Bowman D; Hoar KM; Stringer B; Ecsedy J; Manfredi MG; Hyer ML
    Mol Cancer Res; 2010 Mar; 8(3):373-84. PubMed ID: 20197380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma.
    Qi W; Cooke LS; Liu X; Rimsza L; Roe DJ; Manziolli A; Persky DO; Miller TP; Mahadevan D
    Biochem Pharmacol; 2011 Apr; 81(7):881-90. PubMed ID: 21291867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
    Qi L; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.
    Shi Y; Felley-Bosco E; Marti TM; Orlowski K; Pruschy M; Stahel RA
    BMC Cancer; 2012 Dec; 12():571. PubMed ID: 23211021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer.
    Menendez JA; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Joven J; Vellon L; Vazquez-Martin A
    Aging (Albany NY); 2011 Nov; 3(11):1063-77. PubMed ID: 22170748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
    Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
    Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
    Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
    Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.
    Sehdev V; Peng D; Soutto M; Washington MK; Revetta F; Ecsedy J; Zaika A; Rau TT; Schneider-Stock R; Belkhiri A; El-Rifai W
    Mol Cancer Ther; 2012 Mar; 11(3):763-74. PubMed ID: 22302096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma.
    Brockmann M; Poon E; Berry T; Carstensen A; Deubzer HE; Rycak L; Jamin Y; Thway K; Robinson SP; Roels F; Witt O; Fischer M; Chesler L; Eilers M
    Cancer Cell; 2013 Jul; 24(1):75-89. PubMed ID: 23792191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer.
    Tentler JJ; Ionkina AA; Tan AC; Newton TP; Pitts TM; Glogowska MJ; Kabos P; Sartorius CA; Sullivan KD; Espinosa JM; Eckhardt SG; Diamond JR
    Mol Cancer Ther; 2015 May; 14(5):1117-29. PubMed ID: 25758253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
    Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
    Zhou N; Singh K; Mir MC; Parker Y; Lindner D; Dreicer R; Ecsedy JA; Zhang Z; Teh BT; Almasan A; Hansel DE
    Clin Cancer Res; 2013 Apr; 19(7):1717-28. PubMed ID: 23403633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.
    Pitts TM; Bradshaw-Pierce EL; Bagby SM; Hyatt SL; Selby HM; Spreafico A; Tentler JJ; McPhillips K; Klauck PJ; Capasso A; Diamond JR; Davis SL; Tan AC; Arcaroli JJ; Purkey A; Messersmith WA; Ecsedy JA; Eckhardt SG
    Oncotarget; 2016 Aug; 7(31):50290-50301. PubMed ID: 27385211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.
    Tomita M; Mori N
    Cancer Sci; 2010 May; 101(5):1204-11. PubMed ID: 20180813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.